User profiles for DAVID SPRIGGS
 | David SpriggsMassachusetts General Hospital Verified email at MGH.HARVARD.EDU Cited by 23994 |
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute …
The optimal design of phase II studies continues to be the subject of vigorous debate,
especially studies of newer molecularly targeted agents. The observations that many new …
especially studies of newer molecularly targeted agents. The observations that many new …
Genomic structure, induction, and production of TNF-alpha.
DR Spriggs, S Deutsch, DW Kufe - Immunology series, 1992 - europepmc.org
The TNF gene is located in close proximity to the HLA-B locus in both humans and mouse.
TNF has a high degree of sequence observation across species, and this is reflected in its …
TNF has a high degree of sequence observation across species, and this is reflected in its …
Detection of circulating tumor necrosis factor after endotoxin administration
HR Michie, KR Manogue, DR Spriggs… - … England Journal of …, 1988 - Mass Medical Soc
Cytokines, products of stimulated macrophages, are thought to mediate many host responses
to bacterial infection, but increased circulating cytokine concentrations have not been …
to bacterial infection, but increased circulating cytokine concentrations have not been …
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial
…, W Tong, R Barakat, DR Spriggs - Journal of Clinical …, 2002 - ascopubs.org
PURPOSE: Few chemotherapy agents are active in leiomyosarcoma (LMS), particularly LMS
that has progressed after doxorubicin treatment. We sought to determine the response to …
that has progressed after doxorubicin treatment. We sought to determine the response to …
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies
…, S Pezzulli, C Canales, A Daud, DR Spriggs - Clinical cancer …, 2002 - AACR
Purpose: The purpose of this study was to evaluate the toxicity and pharmacodynamic
behavior of the novel proteasome inhibitor PS341 administered as a twice weekly iv bolus for 2 …
behavior of the novel proteasome inhibitor PS341 administered as a twice weekly iv bolus for 2 …
Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation.
DE Hallahan, DR Spriggs, MA Beckett… - Proceedings of the …, 1989 - National Acad Sciences
We report that tumor necrosis factor alpha (TNF-alpha) mRNA is increased after treatment
with x-rays in certain human sarcoma cells. An increase in TNF-alpha mRNA is accompanied …
with x-rays in certain human sarcoma cells. An increase in TNF-alpha mRNA is accompanied …
CA‐125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a gynecologic oncology …
…, FM Muggia, PG Rose, D Spriggs… - … Journal of the …, 2009 - Wiley Online Library
BACKGROUND: There are limited data regarding unique clinical or laboratory features
associated with advanced clear cell (CC) and mucinous (MU) epithelial ovarian cancers (EOC), …
associated with advanced clear cell (CC) and mucinous (MU) epithelial ovarian cancers (EOC), …
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
M Koneru, TJ Purdon, D Spriggs, S Koneru… - …, 2015 - Taylor & Francis
A novel approach for the treatment of ovarian cancer includes immunotherapy with genetically
engineered T cells targeted to ovarian cancer cell antigens. Using retroviral transduction, …
engineered T cells targeted to ovarian cancer cell antigens. Using retroviral transduction, …
BRCA1 Up-Regulation Is Associated with Repair-mediated Resistance to cis-Diamminedichloroplatinum(II)
A Husain, G He, ES Venkatraman, DR Spriggs - Cancer research, 1998 - AACR
We sought to identify novel genes associated with cis-diamminedichloroplatinum(II) (CDDP)
resistance, and by differential display analysis, we found that the human breast and ovarian …
resistance, and by differential display analysis, we found that the human breast and ovarian …
[HTML][HTML] Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
… David Spriggs … Koneru, M., Purdon, TJ, Spriggs, D., Koneru, S. & Brentjens, RJ IL-12
secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. …
secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. …